

Pfizer Independent Medical Education RFP

Increasing Awareness and Understanding of Duchenne Muscular Dystrophy (DMD)

Competitive Grant Program – Pfizer Internal Review Process



Overview

This competitive grant program seeks to encourage organizations to submit grant applications for educational activities focused on the diagnosis, management and, treatment of Duchenne Muscular Dystrophy (DMD).



Geographic Scope

Latin America, Africa, Middle East and Asia-Pacific (except South Korea, Japan, China, New Zealand & Australia).



Project Types and Area of Interest

Potential applicants are encouraged to identify and address the educational needs of healthcare professionals to increase awareness of DMD, treatment and assessment, and early patient referral and identification through an evidence-based approach.



Key Milestones

- Application submission deadline: September 21, 2023
- Anticipated decision notification date: November 15, 2023
- Anticipated project start date: on or after December 20, 2023



Funding Range and Project Length

Individual projects requesting up to \$100,000 will be considered. Pfizer anticipates awarding up to 3 projects.

I. Eligibility

Geographic Scope:

- Latin America, Africa, Middle East and Asia-Pacific (except South Korea, Japan, China, New Zealand & Australia).
- *(Proposals may be for a single country, a single region, or for a global effort including all countries of interest.)*

Applicant Eligibility Criteria

- Only organizations including non-profit are eligible to receive grants, not individuals or private medical practice groups.
- The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead's grant coordinator).
- The project/program lead must be an employee or independent contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
- For projects offering continuing education credit, the requesting organization must be accredited.

II. Requirements

Date RFP Issued:

- August 10, 2023

Clinical Area:

- Duchenne Muscular Dystrophy (DMD)

General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on:

- Educating healthcare professionals, with a focus on awareness, early referral, and identification of DMD through an evidence-based approach.
- Increasing awareness of at-risk, undiagnosed, and underserved populations with DMD, with a focus on improving systematic strategies that facilitate the appropriate diagnosis of patients early in the disease course before non-ambulation has ensued.
- Identifying and addressing barriers that contribute to geographic, gender, and racial healthcare disparities disproportionately impacting DMD patients to increase earlier diagnosis and treatment.
- Addressing challenges to identify, manage, and care for DMD patients during an era of increased telehealth utilization and digital initiatives, including continuity of care, appropriate diagnoses, patient

referrals, and support for the referral base needs of patients at risk of DMD.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience:

- Physicians such as, pediatricians, neurologists, neuromuscular specialists, pediatric neurologists, geneticists, family physicians, and other specialists who manage patients with DMD.

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to \$100,000 will be considered. Pfizer anticipates awarding up to 3 projects.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:

- RFP release date: August 10, 2023
- Grant Application due date: September 21, 2023
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: November 15, 2023
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: on or after December 20, 2023

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]
- Click the “Start A New Knowledge Gap Application” button.
- In the application:
 - For the question “What type of request are you submitting?” select **Response to a Request for Proposal (RFP)**
 - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select **Yes**
 - Select the following Competitive Grant Program Name: **2023 RD EM DMD Education IME**
 - Select the following Primary Area of Interest: **Duchenne Muscular Dystrophy**
- Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Miguel Briceno (gmg-latam@pfizer.com), with the subject line “**Increasing Awareness and Understanding of Duchenne Muscular Dystrophy (DMD) – August 10, 2023**”

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

Review and Approval Process:

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project

- Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe the planned project, the educational approach, and the way the planned methods address the established need.

Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget please keep the following items in mind:
 - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
 - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please [click here](#) for details.